t-tucb and Visceral-Pain

t-tucb has been researched along with Visceral-Pain* in 1 studies

Other Studies

1 other study(ies) available for t-tucb and Visceral-Pain

ArticleYear
Synthesis, In Vitro Profiling, and In Vivo Evaluation of Benzohomoadamantane-Based Ureas for Visceral Pain: A New Indication for Soluble Epoxide Hydrolase Inhibitors.
    Journal of medicinal chemistry, 2022, 10-27, Volume: 65, Issue:20

    The soluble epoxide hydrolase (sEH) has been suggested as a pharmacological target for the treatment of several diseases, including pain-related disorders. Herein, we report further medicinal chemistry around new benzohomoadamantane-based sEH inhibitors (sEHI) in order to improve the drug metabolism and pharmacokinetics properties of a previous hit. After an extensive in vitro screening cascade, molecular modeling, and in vivo pharmacokinetics studies, two candidates were evaluated in vivo in a murine model of capsaicin-induced allodynia. The two compounds showed an anti-allodynic effect in a dose-dependent manner. Moreover, the most potent compound presented robust analgesic efficacy in the cyclophosphamide-induced murine model of cystitis, a well-established model of visceral pain. Overall, these results suggest painful bladder syndrome as a new possible indication for sEHI, opening a new range of applications for them in the visceral pain field.

    Topics: Analgesics; Animals; Capsaicin; Cyclophosphamide; Disease Models, Animal; Enzyme Inhibitors; Epoxide Hydrolases; Humans; Mice; Urea; Visceral Pain

2022